Free Trial

Aprea Therapeutics (APRE) Competitors

Aprea Therapeutics logo
$1.80 +0.07 (+4.05%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.86 +0.05 (+3.06%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

APRE vs. BRNS, MRSN, ARTV, ELYM, XLO, ATHE, LVTX, LTRN, CLNN, and RNTX

Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Barinthus Biotherapeutics (BRNS), Mersana Therapeutics (MRSN), Artiva Biotherapeutics (ARTV), Eliem Therapeutics (ELYM), Xilio Therapeutics (XLO), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Clene (CLNN), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.

Aprea Therapeutics vs. Its Competitors

Aprea Therapeutics (NASDAQ:APRE) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

In the previous week, Barinthus Biotherapeutics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Aprea Therapeutics Neutral
Barinthus Biotherapeutics Neutral

Aprea Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.8, suggesting that its stock price is 180% less volatile than the S&P 500.

Aprea Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 761.11%. Barinthus Biotherapeutics has a consensus price target of $6.25, indicating a potential upside of 534.52%. Given Aprea Therapeutics' higher possible upside, equities research analysts plainly believe Aprea Therapeutics is more favorable than Barinthus Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aprea Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Barinthus Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aprea Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aprea Therapeutics$1.50M6.64-$12.96M-$2.37-0.76
Barinthus Biotherapeutics$14.97M2.65-$61.07M-$1.64-0.60

Barinthus Biotherapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Barinthus Biotherapeutics' return on equity of -46.43% beat Aprea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aprea Therapeutics-1,095.02% -68.39% -55.74%
Barinthus Biotherapeutics N/A -46.43%-38.50%

Summary

Barinthus Biotherapeutics beats Aprea Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APRE vs. The Competition

MetricAprea TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.57M$2.87B$5.50B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-0.7620.8026.9720.11
Price / Sales6.64286.31425.92119.81
Price / CashN/A41.1936.8257.86
Price / Book0.517.487.985.56
Net Income-$12.96M-$55.04M$3.16B$248.40M
7 Day Performance5.88%2.44%2.36%4.67%
1 Month Performance-2.17%1.90%2.15%6.64%
1 Year Performance-52.13%4.35%33.78%21.31%

Aprea Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APRE
Aprea Therapeutics
2.5069 of 5 stars
$1.80
+4.0%
$15.50
+761.1%
-52.9%$9.57M$1.50M-0.767
BRNS
Barinthus Biotherapeutics
2.5496 of 5 stars
$0.93
+1.5%
$6.25
+572.0%
-31.1%$36.95M$14.97M-0.57107News Coverage
MRSN
Mersana Therapeutics
3.6595 of 5 stars
$0.30
+1.7%
$5.20
+1,656.8%
-82.6%$36.27M$40.50M-0.50150
ARTV
Artiva Biotherapeutics
2.0189 of 5 stars
$1.51
+2.7%
$17.80
+1,078.8%
N/A$35.81M$250K0.0081Gap Up
ELYM
Eliem Therapeutics
N/A$1.18
-6.3%
N/A-81.1%$35.11MN/A-2.239High Trading Volume
XLO
Xilio Therapeutics
2.7432 of 5 stars
$0.68
+0.7%
$4.00
+488.3%
-26.8%$34.97M$6.34M-0.8170Positive News
ATHE
Alterity Therapeutics
2.6269 of 5 stars
$4.09
+4.1%
$12.00
+193.4%
+129.5%$34.88MN/A0.0010
LVTX
LAVA Therapeutics
1.8143 of 5 stars
$1.32
+0.8%
$3.17
+139.9%
-26.7%$34.46M$11.98M-1.2760Positive News
LTRN
Lantern Pharma
2.6152 of 5 stars
$3.16
-0.9%
$25.00
+691.1%
-13.0%$34.40MN/A-1.7220News Coverage
Positive News
CLNN
Clene
2.6663 of 5 stars
$3.91
+4.0%
$40.00
+923.0%
-45.3%$33.78M$340K-0.97100Gap Up
RNTX
Rein Therapeutics
N/A$1.40
-4.8%
N/AN/A$32.57MN/A-0.499High Trading Volume

Related Companies and Tools


This page (NASDAQ:APRE) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners